At midday on Monday, the AIM All Share index remained under pressure down two points at 711.47 and threatening a retest of pre-Christmas lows. The last time we traded below 700 was in November 2023.
- Blue Star Capital +50%
- Trellus Health +23%
- Distil +12%
- tinyBuild -33%
- Eagle Eye -23%
Blue Star Capital LON:BLU was leading the board mid-session with gains of 50%. Two stake building announcements this morning appear to have been the catalyst behind the move, although volumes are thin and the gain is in line with the currently quoted spread. The stock was consolidated last week, which is skewing performance figures.
- AIM Market Roundup: Blue Star Capital, Enteq, Fiinu
- AIM Market Roundup: Trellus, Falcon Oil, MyHealthChecked
Trellus Health LON:TRLS was in second place at our early copy time, up 23%. Last week, the company announced in a slightly under the radar way that they would be speaking at the JP Morgan healthcare conference which kicks off today, something that has form for giving stocks a boost.
- AIM Market Roundup: Trellus, Falcon Oil, MyHealthChecked
- Small Cap Stocks: Trellus Health, Polarean Imaging, Arkle Resources
Distil LON:DIS gets the notable mention, up 12%. The drinks company revealed this morning that Dr Graham Cooley – formerly CEO of ITM Power – had increased his stake in the company to give him 13.2% of the voting rights.
- AIM Market Roundup: Fiinu, Catenai, Frontier Developments
- Small Cap Stocks: Good Energy, Distil, Corcel
tinyBuild [LON:TBLS] was the biggest faller, off by 33% although there’s no news in play and no volume, so this is at least for now a calculation issue.
- Small Cap Stocks: Brand Architekts, tinybuild, Quadrise
- Small Cap Stocks: Empyrean, Beacon Energy, Bushveld Minerals
Eagle Eye Solutions LON:EYE was off 23% following corporate releases this morning. A multi-year global OEM deal which comes with opportunities for significant ARR contributions once live was noted, but the half year trading update came with a cautious tone, noting that a reduction in professional services revenues and longer lead times would result in income for FY 25 and 26 being 15% and 18% lower than expected.